Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504

A302

Abstracts

2022-RA-1117-ESGO

RECYCLING OF DISCARDED OVARIAN CANCER ASCITES TO MONITOR THERAPY RESISTANCE

1Mariana Oliveira Nunes, 1,2Diana Almeida Nunes, 2Miguel Abreu, 2,3Carla Bartosch, 1Sara Ricardo, 1Institute for Research and Innovation in Health (i3S) of the University of Porto, Porto, Portugal; 2School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal; 3TORRUN – Toxicology Research Unit, University Institute of Health Sciences, CESPU, Gandia, Portugal; 4Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), 4200–162 Porto, Portugal, Porto, Portugal; 5TOXRUN – Toxicology Research Unit, University Institute of Health Sciences, CESPU, Gandia, Portugal; 6Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200–162 Porto, Portugal, Porto, Portugal; 7Oncology Institute of Porto (CI-IPOP), Porto, Portugal; 8Center of Belarus, p.Lesnoy, Belarus

10.1136/ijgc-2022-ESGO.643

Introduction/Background Ovarian cancer ascites is one of the signs of ovarian cancer (OC) metastization in the peritoneum and is found in patients at the time of diagnosis and in disease relapse. This serous fluid is used for the initial cytopathological diagnosis and is frequently drained from the peritoneal cavity at advanced stages only for symptomatic relief (and is discarded). In the ovarian cancer context, the presence of ascites is a unique opportunity to monitor the tumor kinetics during disease progression without additional invasive procedures. The main aim of this work was to evaluate the potential of this usually discarded biological material to evaluate the expression of proteins associated with therapy resistance in ovarian cancer ascites cells during disease progression.

Methodology We received ascites from OC patients at diagnosis (n=7) and during treatment (n=8). After centrifugation, samples were formalin-fixed and embedded in Histogel before standard histological processing. Next, immunocytochemistry was performed to assess the expression of three biomarkers associated with chemoresistance in ovarian cancer (ALDH1, SOX2, and Pgp).

Results The majority of our samples had a sufficient number of cells to perform a diversity of histological-based techniques and other molecular studies. The expression of cancer stem cell markers ALDH1 and SOX2 was frequently negative. However, SOX2 and ALDH1 were expressed in samples obtained after chemotherapy. Multi-drug resistance marker (Pgp) expression was negative in samples at diagnosis but was found positive, especially in samples from patients with refractory ascites and without clinical response to treatment.

Conclusion The multidimensional potential ovarian cancer ascites as a spontaneous ‘liquid biopsy’ remains underexplored. Our results show that the use of immunocytochemistry to evaluate resistance biomarkers in tumor cells present in ascites drained from patients during treatment has the potential to predict response to treatment.

2022-RA-1119-ESGO

BURDENED FAMILY HISTORY IN PATIENTS WITH OVARIAN CANCER: RETROSPECTIVE MONOCENTRIC STUDY

1Hanna Trukhan, 2Yuliya Lufiarova Lufiarova, 3Yolha Ramanovich, 4Sergey Mavrichev, 5Elena Dalamanava. 1Gynecologic Oncology, University of Ottawa, Ottawa, ON, Canada; 2Gynecologic Oncology, Trillium Health Partners, Mississauga, ON, Canada; 3Gynecologic Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; 4Department of Medical Oncology, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal; 5Oncogynecologic Department, NN Alexandrov National Cancer Centre of Belarus, p.Lesnoy, Belarus

10.1136/ijgc-2022-ESGO.644

Introduction/Background It’s very important to identify individuals with high genetic risk of developing cancer for prevention of familial ovarian cancer forms, their follow-up management and timely preventive care. A burdened family history (BFH) of cancer is unquestionable and most important indication for genetic testing. Objective: To assess the BFH in patients with ovarian cancer (OC), fallopian tube carcinoma (FTC), primary peritoneal carcinoma (PPC).

Methodology All women with OC, FTC and PPC, who treated at oncogynecologic department N.N. Alexandrov National Cancer Centre of Belarus between January 2022 and May 2022 were retrospectively identified. The main criteria were serous carcinoma, endometrioid carcinoma and clear cell carcinoma. All patients filled out BFH questionnaires. Analysis of the normality of data distribution was carried out on the basis of the Shapiro-Wilk’s W test. The Mann-Whitney U-test was used to compare two independent samples.

Results A total of 92 patients were analyzed: 81 patients with OC, 9 with FTC, 2 with PPC. The mean was 54.5 years, high grade serous carcinoma was the predominant (87%). The majority of patients were of Belarusian (93.5%). 53 (57.6%) women were in menopause at the time of diagnosis, in premenopause was less (28.3%). Most of the study participants had pregnancies, children, lactation were noted (88.0%, 84.8%, 71.7%, respectively). Only 15.2% of women indicated the use of contraceptives. A BFH was noted in 58 (63.0%) patients, it was absent in 34 (17%) patients. The average age of women with a BFH was 53.2 years, without – 56.7 years. There were no statistically significant differences in the groups of patients without and with a BFH, depending on age, diagnosis, histological variant of the tumor (p>0.05).

Conclusion Presence of burdened family history revealed in most cases (63% patients with OC, FTC, PPC) requires further genetic testing.

2022-RA-1127-ESGO

THE EFFICACY OF MEK INHIBITORS IN THE TREATMENT OF LOW-GRADE SEROUS OVARIAN CANCERS: A SYSTEMATIC REVIEW

1Anjali Kulkami, 1Carly M Cooke, 1Michael Fung-Kee-Fung, 2Taymaa May, 3Tiffany Zigras. 1Gynecologic Oncology, University of Ottawa, Ottawa, ON, Canada; 2Gynecologic Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; 3Gynecologic Oncology, Trillium Health Partners, Mississauga, ON, Canada

10.1136/ijgc-2022-ESGO.645

Introduction/Background The low response rates to traditional systemic therapies prompts the need for novel therapies in the treatment of LGSC. LGSC tumors have demonstrated a high frequency of mutations in the MAPK cascade, which is targeted by MEKi. The primary objective of this systematic review was to assess the overall response rate (ORR) of LGSC to MEKi.

Methodology Pubmed, EMBASE, Medline and the Cochrane Database were searched from inception to March 2022. Inclusion criteria were studies assessing the treatment of LGSC in the primary or recurrent setting with the use of a MEKi, published in English. Case reports, case series, conference proceedings, in vitro studies and animal studies were excluded. Studies were screened and assessed for eligibility by two independent reviewers (AK, CC), with conflicts resolved by a third reviewer (TZ). Data was extracted using pre-established criteria.
Results The initial literature search identified 1815 papers; four met the eligibility criteria. Three were randomized clinical trials and one was a phase II single-arm prospective cohort study. MEKI investigated included: pimasertib, selumetinib, trametinib, and binimetinib. A total of 680 patients were included in these studies, of which 416 were treated with a MEKi alone. All patients were treated for recurrent LGSOC. Objective response rates (ORR) to MEKis ranged from 12.1 to 26% and median progression-free survival (PFS) ranged from 7.2 to 13 months.

Conclusion While one study demonstrated significantly improved efficacy of a MEKi over physician-choice systemic therapy in the treatment of recurrent LGSC, another did not show significant benefit. Two additional studies did not compare MEKis to current traditional chemotherapy or hormonal therapies used in the management of LGSC, limiting their clinical relevance. Mutation profiles within the tumors may affect the ORR to various MEKis. Further prospective and randomized trials are needed to determine the efficacy of MEKis in treating LGSC.

Abstract 2022-RA-1133-ESGO Figure 1

Conclusion HSUVs for each line of therapy showed considerable heterogeneity, likely due to variability of data sources and differences in patient populations. Careful deliberation should be taken when conducting cost-utility analyses in patients with ovarian cancer.

2022-RA-1134-ESGO

FIRST REAL-LIFE DATA ON NIRA PARIB MAINTENANCE IN NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER: A DESCRIPTIVE ANALYSIS OF THE TEMPORARY AUTHORIZATION FOR USE (ATU) COHORT

Introduction/Background Niraparib is a PARP inhibitor approved in Europe as maintenance monotherapy in advanced ovarian cancer (aOC) after response to 1L platinum-based chemotherapy. PRIMA/ENGOT-ov26/GOG-3012 showed significant improvement in progression-free survival in aOC with niraparib versus placebo. An early access program (cohort [c] ATU) in France allowed real-world patients with newly-diagnosed aOC who had limited treatment options to receive 1L maintenance treatment with niraparib, when bevacizumab maintenance was not an option for BRCA wild-type patients.

Methodology Patients with newly-diagnosed aOC, including patients without residual disease (RD), were eligible if they had response following platinum-based chemotherapy, were not eligible for bevacizumab, and lacked a BRCA mutation. Niraparib was administered orally (200/300 mg/day) by baseline weight and plateau count.

Results From August 2020-March 2021, 67 oncologists from 55 hospitals completed evaluations for 82 patients with newly-diagnosed aOC; 73 met all eligibility criteria; 67 were exposed to niraparib. Baseline characteristics (table 1) showed...